login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
FEMASYS INC (FEMY) Stock News
USA
- NASDAQ:FEMY -
US31447E1055
-
Common Stock
0.8266
USD
-0.14 (-14.1%)
Last: 11/13/2025, 8:00:01 PM
0.83
USD
+0 (+0.41%)
Pre-Market:
11/14/2025, 4:00:00 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FEMY Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Femasys Inc.
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
4 days ago - By: Femasys Inc.
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
4 days ago - By: Benzinga
- Mentions:
SRDX
WORX
IONS
GTBP
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
7 days ago - By: Benzinga
- Mentions:
CDXS
WORX
IRD
SINT
...
12 Health Care Stocks Moving In Friday's After-Market Session
10 days ago - By: Stocktwits
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing
a month ago - By: Femasys Inc.
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
11 days ago - By: Femasys Inc.
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
11 days ago - By: Femasys Inc.
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
23 days ago - By: Femasys Inc.
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
23 days ago - By: Femasys Inc.
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
a month ago - By: Femasys Inc.
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
2 months ago - By: Femasys Inc.
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
2 months ago - By: Femasys Inc.
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
2 months ago - By: Femasys Inc.
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
2 months ago - By: Femasys Inc.
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
2 months ago - By: Femasys Inc.
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
2 months ago - By: Femasys Inc.
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
2 months ago - By: Femasys Inc.
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
2 months ago - By: Femasys Inc.
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
2 months ago - By: Femasys Inc.
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
Please enable JavaScript to continue using this application.